Page 171 - 2020_07-Haematologica-web

Pre-treatment PET in advanced FL
Hicks RJ. Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2008;71(1):213-219.
6. Luminari S, Biasoli I, Arcaini L, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retro- spective study from the FOLL05 random- ized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013;24(8):2108-2112.
7. Janikova A, Bolcak K, Pavlik T, Mayer J, Kral Z. Value of [18F]fluorodeoxyglucose positron emission tomography in the man- agement of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma. 2008;8(5):287-293.
8. Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of 18F- FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307- 2314.
9. Chen YK, Yeh CL, Tsui CC, Liang JA, Chen JH, Kao CH. F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med. 2011 Jul;36(7):553-559.
10. Smith SD, Redman M, Dunleavy K. FDG PET-CT in follicular lymphoma: a case- based evidence review. Blood. 2015; 125(7):1078-1082.
11. Schoder H, Noy A, Gonen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non- Hodgkin's lymphoma. J Clin Oncol. 2005;23(21):4643-4651.
12. Bodet-Milin C, Kraeber-Bodere F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histologi- cal transformation of indolent lymphoma. Haematologica. 2008;93(3):471-472.
13. Noy A, Schoder H, Gonen M, et al. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scan- ning similar to diffuse large B-cell lym- phoma (DLBCL). Ann Oncol. 2009; 20(3):508-512.
14. Karam M, Feustel PJ, Vera CD, Nazeer T. Features of large cell transformation of indo- lent lymphomas as observed on sequential PET/CT. Nucl Med Commun. 2011;32(3): 177-185.
15. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological vari- ants of 18-fluoro-2-deoxyglucose positron- emission tomography scanning: potential for error in interpretation. Semin Nucl Med. 1996;26(4):308-314.
16. Hofman MS, Hicks RJ. Imaging in follicular NHL. Best Pract Res Clin Haematol. 2011;24(2):165-177.
17. Abou-Nassar KE, Vanderplas A, Friedberg JW, et al. Patterns of use of 18-fluoro-2- deoxy-D-glucose positron emission tomog- raphy for initial staging of grade 1-2 follicu- lar lymphoma and its impact on initial treat- ment strategy in the National Comprehensive Cancer Network Non- Hodgkin Lymphoma Outcomes database. Leuk Lymphoma. 2013;54(10):2155-2162.
18. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, ran- domised controlled trial. Lancet. 2011; 377(9759):42-51.
19. Luminari S, Biasoli I, Versari A, et al. The
prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a sub- set analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25(2):442-447.
20. Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction thera- py is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29(23):3194-3200.
21. Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor bur- den follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol. 2012;30(35):4317-4322.
22. Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemother- apy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1530-1542.
23. Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-ritux- imab or R-CHOP/R-CVP in first-line treat- ment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944- 2952.
24. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, ran- domised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210.
25. Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med. 2018;379(10):934-947.
26. Nastoupil LJ, McLaughlin P, Feng L, et al. High ten-year remission rates following rit- uximab, fludarabine, mitoxantrone and dex- amethasone (R-FND) with interferon main- tenance in indolent lymphoma: Results of a randomized Study. Br J Haematol. 2017;177 (2):263-270.
27. Martinelli G, Schmitz SF, Utiger U, t al. Long-term follow-up of patients with follic- ular lymphoma receiving single-agent ritux- imab at two different schedules in trial SAKK 35/98. J Clin Oncol. 2010;28(29): 4480-4484.
28. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognos- tic index. Blood. 2004;104(5):1258-1265.
29. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognos- tic index 2: a new prognostic index for follic- ular lymphoma developed by the interna- tional follicular lymphoma prognostic factor project. J Clin Oncol. 2009; 27(27):4555- 4562.
30. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15(3):1110-1117.
31. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-3068.
32. Pinnix CC, Ng AK, Dabaja BS, et al. Positron emission tomography-computed tomogra- phy predictors of progression after DA-R- EPOCH for PMBCL. Blood Adv. 2018;2(11): 1334-1343.
33. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consen- sus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048-3058.
34. Falchi L, Keating MJ, Marom EM, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123(18):2783-2790.
35. Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcomes of follicular lymphoma transformation in the immunochemothera- py era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013;31(26):3272-3278.
36. Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lym- phoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126(7):851-857.
37. Alonso-Alvarez S, Magnano L, Alcoceba M, et al. Risk of, and survival following, histo- logical transformation in follicular lym- phoma in the rituximab era. A retrospective multicentre study by the Spanish GELTA- MO group. Br J Haematol. 2017; 178(5):699- 708.
38. Gleeson M, Hawkes EA, Peckitt C, et al. Outcomes for transformed follicular lym- phoma in the rituximab era: the Royal Marsden experience 2003-2013. Leuk Lymphoma. 2017;58(8):1805-1813.
39. Flinn IW, van der Jagt R, Kahl B, et al. First- line treatment of patients with indolent non- Hodgkin lymphoma or mantle-cell lym- phoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-Year follow-up Study. J Clin Oncol. 2019;37(12):984-991.
40. Casulo C, Burack WR, Friedberg JW. Transformed follicular non-Hodgkin lym- phoma. Blood. 2015;125(1):40-47.
41. Nair R, Neelapu SS. The promise of CAR T- cell therapy in aggressive B-cell lymphoma. Best Pract Res Clin Haematol. 2018; 31(3):293-298.
42. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabta- gene ciloleucel in refractory large B-cell lym- phoma (ZUMA-1): a single-arm, multicen- tre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42.
43. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
44. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refrac- tory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45-56.
45. Kinahan PE, Fletcher JW. Positron emis- sion tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31(6): 496-505.
46. Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multi- center studies. J Clin Oncol. 2016; 34(30): 3618-3626.
haematologica | 2020; 105(7)
1913